Humanigen Inc

+0.33 (+3.19%)
Products, Regulatory

Humanigen Announces Lenzilumab In Covid-19 Program Updates

Published: 10/02/2020 11:29 GMT
Humanigen Inc (HGEN) - Humanigen Announces Lenzilumab in Covid-19 Program Updates.
Humanigen Inc - Type B Meeting With FDA Provided Feedback on Emergency Use Authorization Submission Plans.
Humanigen Inc - Phase 3 Trial Expanded to Brazil With Seven Sites Actively Enrolling; Patients Already Dosed.
Humanigen Inc - Top-line Data Planned for Q4 of 2020.
Humanigen Inc - FDA Agreed That Company's Intended Submission May Be Sufficient to Support an Eua Request, Subject to Phase 3 Trial Data.
Humanigen Inc - FDA Provided Guidance and Support for Company's Biologics License Application and Approval Pathway.
Humanigen Inc - Phase 3 Registration Study With Lenzilumab Has Been Approved to Expand to Mexico.